Condition: Aortic Stenosis · Cardiogenic Shock · Sponsor: Rigshospitalet, Denmark
The goal of this clinical trial is to learn if acute transcatheter aortic valve implantation (TAVI) is superior to standard treatment (stabilization in an intensive care unit and TAVI subsequently) to treat cardiogenic shock in patients with critical severe aortic stenosis. The main questions it aims to answer are: • Does acute TAVI increase survival compared with standard treatment? Participants will: * Undergo either TAVI within 12 hours after admission or stabilization and TAVI 72 hours or more after admission * Visit an outpatient clinic and be evaluated for quality of life and heart function
This description comes directly from the study's public registry record.
Emil L Fosbøl, Professor, MD, PhD · 004535456340 · emil.fosboel@regionh.dk
Jarl E Strange, MD, PhD · 004560616598 · jarl.emanuel.strange.02@regionh.dk
Always discuss trial participation with your own doctor first.
| Rigshospitalet Copenhagen University Hospital | Copenhagen O, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06638268